Design and Efficient Synthesis of New 4-Amino-Substituted 2-(4-Bromobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines of Anticancer Interest and Their In Silico Study

Sahil Arora; Shikha Thakur; Venkata Rao Kaki; Raj Kumar

doi:10.1055/a-2367-1675

Synthesis, Table of Contents

Synthesis 2025; 57(01): 240-250
DOI: 10.1055/a-2367-1675

paper

Special Topic Dedicated to Prof. H. Ila

Design and Efficient Synthesis of New 4-Amino-Substituted 2-(4-Bromobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines of Anticancer Interest and Their In Silico Study

Authors

Sahil Arora

^aLaboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda 151 401, India
Shikha Thakur

^aLaboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda 151 401, India
Venkata Rao Kaki

^bDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India
Raj Kumar ∗

^aLaboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda 151 401, India

Abstract

All articles of this category

Abstract

Thienopyrimidines are an emerging class of fused pyrimidines due to their broad spectrum of pharmacological properties, including antimicrobial, anti-inflammatory, antimalarial, anticancer, etc. The anticancer activity of these compounds has been mechanistically proven via the inhibition of validated drug targets, such as EGFR, VEGFR-2, PI3K, and c-kit. In this research article, we designed and synthesized new 4-amino-substituted 2-(4-bromobenzyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidines to explore their anticancer potential. These heterocycles were designed based on pharmacophoric features of the core heterocycle, varying its C4 substitution with a variety of amines and considering cancer protein-ligand interactions with the aim to obtain potent lead molecules. The target compound-protein interaction complexes were analyzed, and lead compounds were identified based on their better binding affinity in molecular docking studies.

Key words

thienopyrimidine - benzo[4,5]thieno[2,3-d]pyrimidines - microwave irradiation - anticancer - synthesis - molecular docking - ADME

Full Text

References

References
1 Joshi G, Nayyar H, Marin Alex J, Vishwakarma GS, Mittal S, Kumar R. Curr. Top. Med. Chem. 2016; 16: 3175
2 Fused Pyrimidine-Based Drug Discovery . Kumar R. Elsevier; Amsterdam: 2022
3 Litvinov VP. Russ. Chem. Bull. 2004; 53: 487
4 Elrazaz EZ, Serya RA. T, Ismail NS. M, Abou El Ella DA, Abouzid KA. M. Future J. Pharm. Sci. 2015; 1: 33
5 Malasala S, Polomoni A, Ahmad MN, Shukla M, Kaul G, Dasgupta A, Chopra S, Nanduri S. J. Mol. Struct. 2021; 1234: 130168
6 Ahmed M, Sayed M, Saber AF, Hassanien R, Kamal El-Dean AM, Tolba MS. Polycyclic Aromat. Compd. 2022; 42: 3079
7 El-Shoukrofy MS, Abd El Razik HA, AboulWafa OM, Bayad AE, El-Ashmawy IM. Bioorg. Chem. 2019; 85: 541
8 Zaidi SL, Agarwal SM, Chavalitshewinkoon-Petmitr P, Suksangpleng T, Ahmad K, Avecilla F, Azam A. RSC Adv. 2016; 6: 90371
9 Bozorov K, Zhao J.-Y, Elmuradov B, Pataer A, Aisa HA. Eur. J. Med. Chem. 2015; 102: 552
10 Shyyka O, Pokhodylo N, Finiuk N, Matiychuk V, Stoika R, Obushak M. Sci. Pharm. 2018; 86: 28
11 Bassetto M, Leyssen P, Neyts J, Yerukhimovich MM, Frick DN, Brancale A. Eur. J. Med. Chem. 2016; 123: 31
12 Miwa K, Hitaka T, Imada T, Sasaki S, Yoshimatsu M, Kusaka M, Tanaka A, Nakata D, Furuya S, Endo S. J. Med. Chem. 2011; 54: 4998
13 Liu Y.-F, Fu S.-Q, Yan Y.-C, Gong B.-B, Xie W.-J, Yang X.-R, Sun T, Ma M. Drug Des., Dev. Ther. 2021; 639
14 Ali EM. H, Abdel-Maksoud MS, Oh C.-H. Bioorg. Med. Chem. 2019; 27: 1159
15 Hasler WL. Curr. Gastroenterol. Rep. 2009; 11: 383
16 Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA. Clin. Cancer Res. 2015; 21: 77
17 Kim D.-W, Lee DH, Han J.-Y, Lee J, Cho BC, Kang JH, Lee KH, Cho EK, Kim J.-S, Min YJ. Lung Cancer 2019; 135: 66
18 Liao B.-C, Lin C.-C, Lee J.-H, Yang JC.-H. J. Biomed. Sci. 2016; 23: 1
19 Porvasnik SL, Germain S, Embury J, Gannon KS, Jacques V, Murray J, Byrne BJ, Shacham S, Al-Mousily F. J. Pharmacol. Exp. Ther. 2010; 334: 364
20 Staben ST, Feng JA, Lyle K, Belvin M, Boggs J, Burch JD, Chua C, Cui H, DiPasquale AG, Friedman LS. J. Med. Chem. 2014; 57: 1033
21 Oslob JD, Romanowski MJ, Allen DA, Baskaran S, Bui M, Elling RA, Flanagan WM, Fung AD, Hanan EJ, Harris S. Bioorg. Med. Chem. Lett. 2008; 18: 4880
22 Sutherlin DP, Sampath D, Berry M, Castanedo G, Chang Z, Chuckowree I, Dotson J, Folkes A, Friedman L, Goldsmith R. J. Med. Chem. 2010; 53: 1086
23 Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R, Gunzner J. J. Med. Chem. 2011; 54: 7579
24 Eissa AA. H. M, Moneer AA. Arch. Pharm. Res. 2004; 27: 885
25 Ravez S, Arsenlis S, Barczyk A, Dupont A, Frédérick R, Hesse S, Kirsch G, Depreux P, Goossens L. Bioorg. Med. Chem. 2015; 23: 7340
26 Mavrova A, Dimov S, Vuchev D, Anichina K, Yancheva D. Lett. Drug Des. Discovery 2018; 15: 887
27 Mghwary AE.-S, Gedawy EM, Kamal AM, Abuel-Maaty SM. J. Enzyme Inhib. Med. Chem. 2019; 34: 838
28 Abdel Fattah B, Kandeel MM, Abdel Hakeem M, Fahmy ZM. J. Chin. Chem. Soc. 2006; 53: 403
29 Sobh EA, Dahab MA, Elkaeed EB, Alsfouk AA, Ibrahim IM, Metwaly AM, Eissa IH. Future Med. Chem. 2023; 15: 1167
30 Bekhit AA, Farghaly AM, Shafik RM, Elsemary MM. A, Bekhit AE.-D. A, Guemei AA, El-Shoukrofy MS, Ibrahim TM. Bioorg. Chem. 2018; 77: 38
31 Bekhit AA, Farghaly AM, Shafik RM, Elsemary MM. A, El-Shoukrofy MS, Bekhit AE.-D. A, Ibrahim TM. Future Med. Chem. 2017; 9: 881
32 Botros S, Khalil OM, Kamel MM, El-Dash YS. Acta Chim. Slov. 2017; 64
33 Elmenier FM, Lasheen DS, Abouzid KA. M. J. Enzyme Inhib. Med. Chem. 2022; 37: 315
34 Elmongy EI, Altwaijry N, Attallah NG. M, AlKahtani MM, Henidi HA. Pharmaceuticals 2022; 15: 170
35 Eissa KI, Kamel MM, Mohamed LW, Galal MA, Kassab AE. Drug Dev. Res. 2022; 83: 1394
36 Motahari R, Boshagh MA, Moghimi S, Peytam F, Hasanvand Z, Oghabi Bakhshaiesh T, Foroumadi R, Bijanzadeh H, Firoozpour L, Khalaj A. Sci. Rep. 2022; 12: 9683
37 Abd ElHadi S. R, Lasheen DS, Hassan MA, Abouzid KA. M. Arch. Pharm. (Weinheim) 2016; 349: 827
38 El-Metwally SA, Khalil AK, El-Sayed WM. Bioorg. Chem. 2020; 94: 103492
39 Arora S, Joshi G, Kalra S, Wani AA, Bharatam PV, Kumar P, Kumar R. ACS Omega 2019; 4: 4604
40 Bhutani P, Joshi G, Raja N, Bachhav N, Rajanna PK, Bhutani H, Paul AT, Kumar R. J. Med. Chem. 2021; 64: 2339
41 Kumar R, Joshi G, Kler H, Kalra S, Kaur M, Arya R. Med. Res. Rev. 2018; 38: 1073
42 Gavali KD, Chaturbhuj GU. SynOpen 2023; 7: 674
43 Kumar D, Kumar R. Tetrahedron Lett. 2014; 55: 2679
44 Joshi G, Chauhan M, Kumar R, Thakur A, Sharma S, Singh R, Wani AA, Sharon A, Bharatam PV, Kumar R. Org. Chem. Front. 2018; 5: 3526
45 Polshettiwar V, Varma RS. Acc. Chem. Res. 2008; 41: 629
46 Maity P, Chatterjee J, Patil KT, Arora S, Katiyar MK, Kumar M, Samarbakhsh A, Joshi G, Bhutani P, Chugh M, Gavande NS, Kumar R. J. Med. Chem. 2023; 66: 3135
47 Tu Y, OuYang Y, Xu S, Zhu Y, Li G, Sun C, Zheng P, Zhu W. Bioorg. Med. Chem. 2016; 24: 1495
48 Kahveci B, Doğan İS, Menteşe E, Sellitepe HE, Kart D. Pharm. Chem. J. 2020; 54: 647
49 Arora S, Joshi G, Chaturvedi A, Heuser M, Patil S, Kumar R. J. Med. Chem. 2022; 65: 1171

Supplementary Material

Supporting Information (PDF) (opens in new window)